ALK and non-small cell lung carcinoma: The lack of molecular profiling limits the ability to stratify patients based on actionable genomic alterations, such as EGFR mutations, ALK rearrangements, or PIG3 mutation in NSCLC, which are associated with distinct metastatic patterns, treatment responses, and prognosis [23,39].